TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?Zacks Investment Research • 09/09/25
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic CancerBusiness Wire • 09/09/25
Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
After An Odd Start, Tempus AI Is Making A Beeline To The Good End Of The AI RainbowSeeking Alpha • 09/08/25
Tempus AI: Strategic AI Advancements In Precision Oncology With Solid Stock Upside PotentialSeeking Alpha • 09/08/25
Tempus AI: Expansive Opportunity As Healthcare Becomes More Heavily ScrutinizedSeeking Alpha • 09/04/25
Northwestern Medicine Becomes First Health System to Integrate Tempus' Generative AI Co-Pilot, David, Into Its EHR PlatformBusiness Wire • 09/04/25
Tempus to Participate in Morgan Stanley's 23rd Annual Global Healthcare ConferenceBusiness Wire • 09/03/25
4 Medical Devices Behemoths to Buy Amid Extensive AI ApplicationsZacks Investment Research • 08/22/25
TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 08/14/25
Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next DecadeBenzinga • 08/14/25
Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold?Zacks Investment Research • 08/13/25
TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?Zacks Investment Research • 08/13/25
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 08/12/25